chartexchange

LENZ
LENZ Therapeutics, Inc. Common Stock
stockNASDAQ

At CloseNov 18, 2026 3:59:57 PM EST
3.20USD-8.571%(-0.30)622,158
After-hoursNov 18, 2026 4:27:30 PM EST
3.16USD-1.250%(-0.04)
Loading…
Loading…
100.55M
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Previous Close
$3.50
Beta
2.15
52-Week High
$32.13 2025-11-24
52-Week Low
$2.80 2026-11-02
SMA 50
$3.69
SMA 200
$7.05
Avg. Vol 10D
854,370
Avg. Vol 30D
1.08M
Avg. Vol 90D
892,950
Relative Vol
0.58
27.17M
1.0700%
475,246
Mar 22, 2024 · 1-for-7 (reverse)
LENZ Profile

graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company's platform harnesses the natural cellular process of homology directed repair (hdr) and targeted dna integration to precisely repair genetic defects at their source. graphite bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients' lives

LENZ Performance
PeriodPriceDateChangeBeta
1W4.092026-11-12-21.76%2.494
1M3.302026-10-19-3.03%4.103
3M4.922026-08-19-34.96%3.632
6M6.652026-05-19-51.88%2.036
1Y28.402025-11-19-88.73%2.146
2Y34.652024-11-19-90.77%—
LENZ Stock Summary

LENZ Therapeutics, Inc. Common Stock (NASDAQ:LENZ) stock price today is $3.20, and today's volume is 622,158. LENZ is down 8.571% today. The 30 day average volume is 1.08M. LENZ market cap is $100.55M with 31.42M shares outstanding.